| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P50 | author | Silvia Franceschi | Q56417107 |
| Peter J F Snijders | Q90768556 | ||
| P2093 | author name string | Ni Li | |
| Gary M Clifford | |||
| Rebecca Howell-Jones | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cervix uterine cancer | Q160105 |
| P304 | page(s) | 927-935 | |
| P577 | publication date | 2011-02-01 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication | |
| P478 | volume | 128 |
| Q39546343 | "Who will take the blame?": understanding the reasons why Romanian mothers decline HPV vaccination for their daughters |
| Q38446093 | 1p36.22 region containing PGD gene is frequently gained in human cervical cancer |
| Q36106799 | A Bivariate Mixture Model for Natural Antibody Levels to Human Papillomavirus Types 16 and 18: Baseline Estimates for Monitoring the Herd Effects of Immunization |
| Q37671558 | A comparison of methylation levels in HPV18, HPV31 and HPV33 genomes reveals similar associations with cervical precancers |
| Q35671337 | A cross-sectional study of high-risk human papillomavirus clustering and cervical outcomes in HIV-infected women in Rio de Janeiro, Brazil |
| Q54222673 | A high prevalence of human papillomavirus 16 and 18 co-infections in cervical biopsies from southern Brazil. |
| Q41376968 | A lectin-based diagnostic system using circulating antibodies to detect cervical intraepithelial neoplasia and cervical cancer |
| Q92680418 | A population-based study of age-related associations between vaginal pH and the development of cervical intraepithelial neoplasia |
| Q38006991 | A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18. |
| Q34708325 | A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls |
| Q38364617 | Adenocarcinoma of the cervix: should we treat it differently? |
| Q59329445 | Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus |
| Q90520710 | Age-specific HPV prevalence among 116,052 women in Australia's renewed cervical screening program: A new tool for monitoring vaccine impact |
| Q57089342 | American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer |
| Q24607403 | American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer |
| Q26828840 | American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. |
| Q37162220 | Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines |
| Q35909330 | An Evaluation of the Cobas4800 HPV Test on Cervico-Vaginal Specimens in Liquid versus Solid Transport Media |
| Q40628968 | An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany |
| Q36468756 | An overview of viral oncology in Italy - report from the Pavia meeting on solid tumors |
| Q35553220 | Anal Human Papillomavirus Genotyping among HIV-Positive Men Who Have Sex with Men in Xi'an, China |
| Q34686633 | Anal and perianal squamous carcinomas and high-grade intraepithelial lesions exclusively associated with "low-risk" HPV genotypes 6 and 11. |
| Q37487505 | Analysis of E2 gene integrity in HPV16 and HPV58 viruses isolated from women with cervical pathology |
| Q47110076 | Analysis of human papilloma virus type 52 integration status in exfoliated cervical cells |
| Q34953460 | Analysis of mutations in the E6 oncogene of human papillomavirus 16 in cervical cancer isolates from Moroccan women |
| Q38368307 | Ancient Evolution and Dispersion of Human Papillomavirus Type 58 Variants |
| Q47319115 | Annual prevalence and economic burden of genital warts in Korea: Health Insurance Review and Assessment (HIRA) service data from 2007 to 2015. |
| Q52631712 | Are two doses of human papillomavirus vaccine sufficient for girls aged 15-18 years? Results from a cohort study in India. |
| Q28082953 | Assessing cost-effectiveness of HPV vaccines with decision analytic models: what are the distinct challenges of low- and middle-income countries? A protocol for a systematic review |
| Q98183610 | Assessment of attribution algorithms for resolving CIN3-related HPV genotype prevalence in mixed-genotype biopsy specimens using laser capture microdissection as the reference standard |
| Q37570000 | Association Between Type-specific HPV Infections and hTERT DNA Methylation in Patients with Invasive Cervical Cancer. |
| Q35691927 | Association Study between Cervical Lesions and Single or Multiple Vaccine-Target and Non-Vaccine Target Human Papillomavirus (HPV) Types in Women from Northeastern Brazil |
| Q37889149 | Association between TNF-α polymorphisms and cervical cancer risk: a meta-analysis |
| Q39604503 | Association between human papillomavirus vaccine uptake and cervical cancer screening in the Netherlands: implications for future impact on prevention |
| Q36174016 | Association of Human Papillomavirus 31 DNA Load with Risk of Cervical Intraepithelial Neoplasia Grades 2 and 3. |
| Q47370960 | Association of p16 (CDKN2A) polymorphisms with the development of HPV16-related precancerous lesions and cervical cancer in the Greek population. |
| Q39700431 | Attribution of human papillomavirus types to cervical intraepithelial neoplasia and invasive cancers in Southern China |
| Q93149210 | Awareness of surgical smoke hazards and enhancement of surgical smoke prevention among the gynecologists |
| Q41928636 | Barriers to cervical cancer screening faced by immigrants: a registry-based study of 1.4 million women in Norway. |
| Q39438673 | Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries |
| Q38170707 | Burden of human papillomavirus infections and related diseases in the extended Middle East and North Africa region |
| Q53229949 | CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer. |
| Q36720252 | CCR2 and CCR5 genes polymorphisms in women with cervical lesions from Pernambuco, Northeast Region of Brazil: a case-control study |
| Q34011249 | Canadian oncogenic human papillomavirus cervical infection prevalence: systematic review and meta-analysis |
| Q90266558 | Cancer prevention: cervical cancer |
| Q41139348 | Carcinogenic ability quantification of human papilloma virus subtypes in eastern China |
| Q40647908 | Cervical Infection With Vaccine-Associated Human Papillomavirus (HPV) Genotypes as a Predictor of Acquisition and Clearance of Other HPV Infections |
| Q37943650 | Cervical adenocarcinoma: moving towards better prevention |
| Q84595950 | Cervical cancer |
| Q40228937 | Cervical cancer in sub-Saharan Africa: a preventable noncommunicable disease |
| Q41126446 | Cervical cancer prevented by screening: Long-term incidence trends by morphology in Norway. |
| Q28601706 | Cervical cancer prevention and treatment research in Africa: a systematic review from a public health perspective |
| Q40432574 | Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference |
| Q38748682 | Cervical cancer: A comprehensive approach towards extermination |
| Q48535452 | Cervical cancer: what is the optimal age for routine testing? |
| Q92474610 | Cervical high-risk human papillomavirus infection among women residing in the Gulf Cooperation Council countries: Prevalence, type-specific distribution, and correlation with cervical cytology |
| Q34340212 | Cervical human papillomavirus prevalence and genotype distribution among hybrid capture 2 positive women 15 to 64 years of age in the Gurage zone, rural Ethiopia |
| Q55034904 | Cervical small cell carcinoma frequently presented in multiple high risk HPV infection and often associated with other type of epithelial tumors. |
| Q40666818 | Challenging 'girls only' publicly funded human papillomavirus vaccination programmes |
| Q34477498 | Changes in antibody seroprevalence of seven high-risk HPV types between nationwide surveillance studies from 1995-96 and 2006-07 in The Netherlands |
| Q35870672 | Characteristics and survival of head and neck cancer by HPV status: a cancer registry-based study |
| Q90092443 | Characteristics of carcinogenic HPV genotypes in North China Plain and the association with cervical lesions |
| Q33703182 | Characterization of HPV DNA methylation of contiguous CpG sites by bisulfite treatment and massively parallel sequencing-the FRAGMENT approach. |
| Q36523118 | Characterization of human papillomavirus type 120: a novel betapapillomavirus with tropism for multiple anatomical niches. |
| Q35656638 | Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia |
| Q36207038 | Claspin as a biomarker of human papillomavirus-related high grade lesions of uterine cervix |
| Q36948919 | Classification and nomenclature system for human Alphapapillomavirus variants: general features, nucleotide landmarks and assignment of HPV6 and HPV11 isolates to variant lineages |
| Q40854884 | Clinical Performance of APTIMA Human Papillomavirus (HPV) 16 18/45 mRNA Genotyping Testing for the Detection of Cervical Intraepithelial Neoplasia 3 (CIN3) or Cancer in a Select Group of Chinese Women |
| Q33703374 | Clinical performance of Roche Cobas 4800 HPV Test |
| Q94585060 | Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening |
| Q40238348 | Cohort Profile: African Collaborative Center for Microbiome and Genomics Research's (ACCME) Human Papillomavirus (HPV) and Cervical Cancer Study |
| Q33798276 | Comparative analysis of HPV16 gene expression profiles in cervical and in oropharyngeal squamous cell carcinoma |
| Q38119752 | Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study |
| Q35886612 | Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study |
| Q47573076 | Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial |
| Q35886910 | Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial |
| Q34938697 | Comparing human papillomavirus prevalences in women with normal cytology or invasive cervical cancer to rank genotypes according to their oncogenic potential: a meta-analysis of observational studies |
| Q39160423 | Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study |
| Q38844434 | Comparison of GeneFinder human papillomavirus (HPV) Liquid Beads Microarray PCR Kit and Hybrid Capture 2 Assay for Detection of HPV Infection. |
| Q37001299 | Comparison of HPV DNA testing in cervical exfoliated cells and tissue biopsies among HIV-positive women in Kenya |
| Q35886468 | Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus |
| Q35342179 | Comparison of analytical and clinical performance of CLART HPV2 genotyping assay to Linear Array and Hybrid Capture 2: a split-sample study |
| Q42235610 | Comparison of digene hybrid capture 2, GeneMatrix PapilloScreen, and a PCR sequencing assay in detecting high-risk and probable high-risk oncogenic HPV genotypes in specimens from Korean women |
| Q36118559 | Comparison of the Abbott RealTime High-Risk Human Papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA. |
| Q33859491 | Comprehensive Human Papillomavirus Genotyping in Cervical Squamous Cell Carcinomas and Its Relevance to Cervical Cancer Prevention in Malawian Women |
| Q36905787 | Comprehensive mapping of the human papillomavirus (HPV) DNA integration sites in cervical carcinomas by HPV capture technology |
| Q55007219 | Computational identification, characterization and validation of potential antigenic peptide vaccines from hrHPVs E6 proteins using immunoinformatics and computational systems biology approaches. |
| Q36468718 | Consistent condom use increases spontaneous regression in high-risk non-HPV16 but not in HPV16 CIN2-3 lesions, a prospective population-based cohort study |
| Q36602973 | Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study |
| Q55114551 | Contribution of Human papillomavirus in neuroendocrine tumors from a series of 10,575 invasive cervical cancer cases. |
| Q37159889 | Correlation between ebv co-infection and HPV16 genome integrity in Tunisian cervical cancer patients |
| Q40421639 | Correlation of human papillomavirus types with clinical features of patients with condyloma acuminatum in China |
| Q39107868 | Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study |
| Q42287707 | Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account |
| Q38776663 | CpG methylation in human papillomavirus (HPV) type 31 long control region (LCR) in cervical infections associated with cytological abnormalities |
| Q30353668 | Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections. |
| Q44350321 | Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial |
| Q40665510 | Decreased RARβ expression induces abundant inflammation and cervical precancerous lesions |
| Q100455076 | Deep sequencing detects human papillomavirus (HPV) in cervical cancers negative for HPV by PCR |
| Q28475532 | Degradation of p53 by human Alphapapillomavirus E6 proteins shows a stronger correlation with phylogeny than oncogenicity |
| Q54310996 | Detection and genotyping of human papillomaviruses and their role in the development of ovarian carcinomas. |
| Q40173405 | Detection of High-Risk Human Papillomavirus Genotypes 16 and 18 in Head and Neck Squamous Cell Carcinomas in Jordan |
| Q51171929 | Detection of rare and possibly carcinogenic human papillomavirus genotypes as single infections in invasive cervical cancer. |
| Q34316637 | Determinants of acceptance and subsequent uptake of the HPV vaccine in a cohort in Eldoret, Kenya |
| Q40910986 | Development of a cervical cancer progress prediction tool for human papillomavirus-positive Koreans: A support vector machine-based approach |
| Q35834831 | Development of a fluorescence-based multiplex genotyping method for simultaneous determination of human papillomavirus infections and viral loads |
| Q36269739 | Development of a simple and quick immunochromatography method for detection of anti-HPV-16/-18 antibodies |
| Q88979450 | Developments in Point-of-Care Diagnostic Technology for Cancer Detection |
| Q83550700 | Different amplification patterns of the human telomerase RNA gene in invasive cervical carcinomas and cervical intraepithelial neoplasia grade III |
| Q38967050 | Differential HPV16 variant distribution in squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma. |
| Q35596183 | Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis |
| Q42277760 | Diseases associated with human papillomavirus infection |
| Q29353543 | Distinctive distribution of HPV genotypes in cervical cancers in multi-ethnic Suriname: implications for prevention and vaccination |
| Q40129728 | Distribution and attribution of high-risk human papillomavirus genotypes in cervical precancerous lesions in China |
| Q64923928 | Distribution and role of high-risk human papillomavirus genotypes in women with cervical intraepithelial neoplasia: A retrospective analysis from Wenzhou, southeast China. |
| Q34412349 | Distribution of high-risk human papillomavirus genotypes among HIV-negative women with and without cervical intraepithelial neoplasia in South Africa |
| Q39745725 | Distribution of human papillomavirus genotypes in Paraguayan women according to the severity of the cervical lesion |
| Q37697709 | Distribution of human papillomavirus genotypes in cervical lesions |
| Q36769394 | Distribution of human papillomaviruses and bacterial vaginosis in HIV positive women with abnormal cytology in Mombasa, Kenya |
| Q37718767 | Dynamics of high-risk nonvaccine human papillomavirus types after actual vaccination scheme |
| Q37325881 | Dysregulation of host cellular genes targeted by human papillomavirus (HPV) integration contributes to HPV-related cervical carcinogenesis |
| Q36264936 | E6 and E7 Gene Polymorphisms in Human Papillomavirus Types-58 and 33 Identified in Southwest China |
| Q36194955 | EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease |
| Q34490403 | Economic burden of human papillomavirus-related diseases in Italy |
| Q39008567 | Ectonucleotidase expression profile and activity in human cervical cancer cell lines. |
| Q37519825 | Effect of HIV Infection on Human Papillomavirus Types Causing Invasive Cervical Cancer in Africa |
| Q39163261 | Effect on HPV vaccination in Japan resulting from news report of adverse events and suspension of governmental recommendation for HPV vaccination |
| Q89916729 | Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study |
| Q42221933 | Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials |
| Q34776171 | Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial. |
| Q37735000 | Enhancement of humoral and cell mediated immune response to HPV16 L1-derived peptides subsequent to vaccination with prophylactic bivalent HPV L1 virus-like particle vaccine in healthy females |
| Q36231336 | Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination |
| Q37078556 | Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination |
| Q36031583 | Epidemiologic characterization of human papillomavirus (HPV) infection in various regions of Yunnan Province of China |
| Q58713772 | Epidemiological and economic burden of potentially HPV-related cancers in France |
| Q37941160 | Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies |
| Q33592432 | Epidemiology and genotype distribution of human papillomavirus (HPV) in Southwest China: a cross-sectional five years study in non-vaccinated women |
| Q35841460 | Epidemiology of, and behavioural risk factors for, sexually transmitted human papillomavirus infection in men and women in Britain. |
| Q90401066 | Establishment and Molecular Phenotyping of Organoids from the Squamocolumnar Junction Region of the Uterine Cervix |
| Q21261267 | Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination |
| Q58023873 | Eurogin Roadmap: Comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix |
| Q36151508 | Evaluation of Association between Vaginal Infections and High-Risk Human Papillomavirus Types in Female Sex Workers in Spain. |
| Q38993490 | Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials |
| Q38679549 | Evidence-based policy choices for efficient and equitable cervical cancer screening programs in low-resource settings. |
| Q34973937 | Evolution and taxonomic classification of alphapapillomavirus 7 complete genomes: HPV18, HPV39, HPV45, HPV59, HPV68 and HPV70. |
| Q21135368 | Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67 |
| Q40092337 | Exosomes and Other Extracellular Vesicles in HPV Transmission and Carcinogenesis |
| Q42215200 | Factors associated with reduced accuracy in Papanicolaou tests for patients with invasive cervical cancer |
| Q93107818 | Genetic diversity and phylogenetic analysis of HPV 16 & 18 variants isolated from cervical specimens of women in Saudi Arabia |
| Q47749312 | Genetic diversity of human papillomavirus types 35, 45 and 58 in cervical cancer in Brazil. |
| Q38646674 | Genetic variability and functional implication of the long control region in HPV-16 variants in Southwest China |
| Q59357470 | Genetic variability and lineage phylogeny of human papillomavirus type 45 based on E6 and E7 genes in Southwest China |
| Q35719168 | Genetic variability and phylogeny of high risk HPV type 16, 18, 31, 33 and 45 L1 gene in Greek women |
| Q31141200 | Genetic variations of E6 and long control region of human papillomavirus type 16 from patients with cervical lesion in Liaoning, China |
| Q42260222 | Genomic diversity of low-risk human papillomavirus genotypes HPV 40, HPV 42, HPV 43, and HPV 44. |
| Q36321058 | Genotype distribution characteristics of multiple human papillomavirus in women from the Taihu River Basin, on the coast of eastern China |
| Q35141881 | Genotypic distribution of human papillomavirus (HPV) and cervical cytology findings in 5906 Thai women undergoing cervical cancer screening programs |
| Q37656606 | Geographical distribution and oncogenic risk association of human papillomavirus type 58 E6 and E7 sequence variations |
| Q35031952 | HIV associated high-risk HPV infection among Nigerian women. |
| Q61480154 | HLA and KIR Associations of Cervical Neoplasia |
| Q38273669 | HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis |
| Q36238070 | HPV Genotyping of Modified General Primer-Amplicons Is More Analytically Sensitive and Specific by Sequencing than by Hybridization. |
| Q47599045 | HPV distribution in cervical cancer in Portugal. A retrospective study from 1928 to 2005. |
| Q31121182 | HPV genotype distribution in Brazilian women with and without cervical lesions: correlation to cytological data |
| Q33848918 | HPV genotypes and cervical intraepithelial neoplasia in a multiethnic cohort in the southeastern USA |
| Q49907625 | HPV genotyping for the cross-sectional and longitudinal probability of developing CIN2. |
| Q42264722 | HPV genotyping in adenocarcinoma of the uterine cervix in Thailand |
| Q64255751 | HPV negative cervical cancers and primary HPV screening |
| Q61447073 | HPV prevalence and genotype distribution among women in Shandong Province, China: Analysis of 94,489 HPV genotyping results from Shandong's largest independent pathology laboratory |
| Q38930783 | HPV prevalence and type-distribution in cervical cancer and premalignant lesions of the cervix: A population-based study from Northern Ireland. |
| Q37204759 | HPV strain distribution in patients with genital warts in a female population sample. |
| Q36480261 | HPV type distribution in invasive cervical cancers in Italy: pooled analysis of three large studies. |
| Q34917796 | HPV types and variants among cervical cancer tumors in three regions of Tunisia |
| Q36856284 | HPV-based Tests for Cervical Cancer Screening and Management of Cervical Disease |
| Q41736026 | HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis |
| Q92614830 | HPV-negative tumors of the uterine cervix |
| Q38069386 | HPV-type has no impact on survival of patients with adenocarcinoma of the uterine cervix |
| Q36901882 | HPV16 CpG methyl-haplotypes are associated with cervix precancer and cancer in the Guanacaste natural history study |
| Q42254022 | HPV16 genotype, p16/Ki-67 dual staining and koilocytic morphology as potential predictors of the clinical outcome for cervical low-grade squamous intraepithelial lesions. |
| Q22299118 | HPV16 variant lineage, clinical stage, and survival in women with invasive cervical cancer |
| Q36307824 | HPV16/18 genotyping for the triage of HPV positive women in primary cervical cancer screening in Chile |
| Q34894228 | Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model |
| Q36133449 | Heterogeneity of high-grade cervical intraepithelial neoplasia related to HPV16: implications for natural history and management |
| Q41130336 | High performance of combined HPV testing and genotyping for HPV16/18/52/58 in triaging women with minor cervical cytological abnormalities in northern Thailand |
| Q37030821 | High prevalence and incidence of human papillomavirus in a cohort of healthy young African female subjects |
| Q46576040 | High prevalence of human papillomavirus infection in Eastern European and West African women immigrants in South Italy |
| Q26825841 | High-Risk HPVs and Human Carcinomas in the Syrian Population |
| Q37509723 | High-risk cervical human papillomavirus infections among human immunodeficiency virus-positive women in the Bahamas |
| Q57061683 | High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study |
| Q39229942 | High-risk human papillomavirus types in HIV-infected and HIV-uninfected young women in KwaZulu-Natal, South Africa: implications for vaccination |
| Q47558350 | Human Papilloma Viruses and Their Genotype Distribution in Women with High Socioeconomic Status in Central Anatolia, Turkey: A Pilot Study. |
| Q36466049 | Human Papillomavirus (HPV) Genotyping: Automation and Application in Routine Laboratory Testing |
| Q36086298 | Human Papillomavirus 18 Genetic Variation and Cervical Cancer Risk Worldwide |
| Q93037522 | Human Papillomavirus 58 E7 T20I/G63S Variant Isolated from an East Asian Population Possesses High Oncogenicity |
| Q33645426 | Human Papillomavirus Genotype Distribution among Cervical Cancer Patients prior to Brazilian National HPV Immunization Program. |
| Q37208823 | Human Papillomavirus Genotype Distribution in Invasive Cervical Cancer in Pakistan |
| Q61161006 | Human Papillomavirus Genotypes in High-Grade Cervical Lesions in the United States |
| Q62490094 | Human Papillomavirus Genotypes in Invasive Cervical Carcinoma in HIV-Seropositive and HIV-Seronegative Women in Zimbabwe |
| Q57089326 | Human Papillomavirus Vaccination: Making Sense of the Public Controversy |
| Q37608182 | Human Papillomavirus types distribution among women with cervical preneoplastic, lesions and cancer in Luanda, Angola |
| Q37923517 | Human papilloma virus (HPV) molecular diagnostics. |
| Q36550149 | Human papillomavirus (HPV) genome status & cervical cancer outcome--A retrospective study |
| Q92617895 | Human papillomavirus (HPV) subtypes and their relationships with cervical smear results in cervical cancer screening: a community-based study from the central Anatolia region of Turkey |
| Q33830609 | Human papillomavirus 16 non-European variants are preferentially associated with high-grade cervical lesions |
| Q41926367 | Human papillomavirus 16L1-58L2 chimeric virus-like particles elicit durable neutralizing antibody responses against a broad-spectrum of human papillomavirus types |
| Q37700184 | Human papillomavirus 33 worldwide genetic variation and associated risk of cervical cancer |
| Q28659720 | Human papillomavirus 45 genetic variation and cervical cancer risk worldwide |
| Q39265001 | Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence |
| Q34731530 | Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. |
| Q89997049 | Human papillomavirus and cervical cancer |
| Q58279986 | Human papillomavirus and cervical cancer |
| Q35805297 | Human papillomavirus antibody reference reagents for use in postvaccination surveillance serology |
| Q27026226 | Human papillomavirus genome variants |
| Q41446278 | Human papillomavirus genotype distribution among Cameroonian women with invasive cervical cancer: a retrospective study. |
| Q56839491 | Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention |
| Q39139886 | Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grade 2/3 and invasive cervical cancer in Japanese women. |
| Q37604761 | Human papillomavirus genotypes associated with cervical precancerous lesions and cancer in the highest area of cervical cancer mortality, Longnan, China |
| Q34863458 | Human papillomavirus genotypes distribution in 175 invasive cervical cancer cases from Brazil |
| Q92585076 | Human papillomavirus genotypes in cervical and other HPV-related anogenital cancer in Rwanda, according to HIV status |
| Q92039393 | Human papillomavirus genotypes in women with invasive cervical cancer with and without human immunodeficiency virus infection in Botswana |
| Q34309947 | Human papillomavirus in head and neck cancer. |
| Q46135972 | Human papillomavirus infection and related cancers in sub-Saharan Africa: burden and tools for prevention |
| Q35187843 | Human papillomavirus infection and sporadic breast carcinoma risk: a meta-analysis |
| Q34469136 | Human papillomavirus infection in Bhutan at the moment of implementation of a national HPV vaccination programme |
| Q34471165 | Human papillomavirus infection in women with and without cervical cancer in Ibadan, Nigeria |
| Q53142963 | Human papillomavirus infection in women with and without cervical cancer in Tehran, Iran. |
| Q36265489 | Human papillomavirus infections among women with cervical lesions and cervical cancer in Eastern China: genotype-specific prevalence and attribution |
| Q42277972 | Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa |
| Q47599112 | Human papillomavirus prevalence and type distribution in urine samples from Norwegian women aged 17 and 21 years: A nationwide cross-sectional study of three non-vaccinated birth cohorts. |
| Q38170766 | Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe. |
| Q34616083 | Human papillomavirus testing in the prevention of cervical cancer |
| Q38853165 | Human papillomavirus type 16 E7 oncoprotein upregulates the retinoic acid receptor-beta expression in cervical cancer cell lines and K14E7 transgenic mice |
| Q90428210 | Human papillomavirus type 18 E5 oncoprotein cooperates with E6 and E7 in promoting cell viability and invasion and in modulating the cellular redox state |
| Q36150544 | Human papillomavirus type 58: the unique role in cervical cancers in East Asia |
| Q34731097 | Human papillomavirus type 6 and 11 genetic variants found in 71 oral and anogenital epithelial samples from Australia |
| Q33750349 | Human papillomavirus type distribution and HPV16 intratype diversity in southern Brazil in women with and without cervical lesions |
| Q38218612 | Human papillomavirus vaccination: where are we now? |
| Q40245504 | Human papillomavirus, Epstein-Barr virus, and methylation status of p16ink4a in penile cancer |
| Q38064064 | Human papillomavirus, human immunodeficiency virus and immunosuppression |
| Q34291224 | Human papillomaviruses-related cancers. Presence and prevention strategies in the Middle east and north African regions |
| Q39909954 | Hybrid Capture 2 and cobas human papillomavirus assays perform similarly on SurePath samples from women with abnormalities. |
| Q31126565 | Identification of episomal human papillomavirus and other DNA viruses in cytological anal samples of HIV-uninfected men who have sex with men. |
| Q42278396 | Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras |
| Q34291136 | Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. |
| Q37703113 | Immunologic treatments for precancerous lesions and uterine cervical cancer |
| Q30682187 | Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study |
| Q47261790 | Impact of organized and opportunistic Pap testing on the risk of cervical cancer in young women - A case-control study from Finland |
| Q35770049 | Implementation of an HPV vaccination program in Eldoret, Kenya: results from a qualitative assessment by key stakeholders |
| Q42244757 | Implication of HLA-G 3' untranslated region polymorphisms in human papillomavirus infection |
| Q95383249 | In inverted papillomas HPV more likely represents incidental colonization than an etiological factor |
| Q30661799 | In silico mechanistic analysis of IRF3 inactivation and high-risk HPV E6 species-dependent drug response |
| Q37648087 | Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004-2013. |
| Q43893716 | Individual and geographic disparities in human papillomavirus types 16/18 in high-grade cervical lesions: Associations with race, ethnicity, and poverty |
| Q27011403 | Infection transmission and chronic disease models in the study of infection-associated cancers |
| Q95840329 | Inferring Virus-Host relationship between HPV and its host Homo sapiens using protein interaction network |
| Q42223991 | Influence of HPV type on prognosis in patients diagnosed with invasive cervical cancer |
| Q38170681 | Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa |
| Q92585765 | Insertional oncogenesis by HPV70 revealed by multiple genomic analyses in a clinically HPV-negative cervical cancer |
| Q91994556 | Key Molecular Events in Cervical Cancer Development |
| Q36278498 | Knowledge, attitudes, practices and willingness to vaccinate in preparation for the introduction of HPV vaccines in Bamako, Mali |
| Q36311573 | Laboratory and clinical aspects of human papillomavirus testing |
| Q51409399 | Long-term incidence trends of HPV-related cancers, and cases preventable by HPV vaccination: a registry-based study in Norway. |
| Q41620477 | Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology. |
| Q38373388 | Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination |
| Q47104315 | Mechanistic signatures of HPV insertions in cervical carcinomas |
| Q59354011 | Meta-Analysis of Polymorphic Variants Conferring Genetic Risk to Cervical Cancer in Indian Women Supports CYP1A1 as an Important Associated Locus |
| Q42197971 | Meta-analysis of type-specific human papillomavirus prevalence in Iranian women with normal cytology, precancerous cervical lesions and invasive cervical cancer: Implications for screening and vaccination |
| Q34207423 | Meta-analysis on prevalence and attribution of human papillomavirus types 52 and 58 in cervical neoplasia worldwide |
| Q24633086 | Methylation of HPV16 genome CpG sites is associated with cervix precancer and cancer |
| Q36606686 | Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. |
| Q35866379 | Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population |
| Q42190856 | Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16. |
| Q39361627 | MicroRNAs in HPV associated cancers: small players with big consequences |
| Q42044915 | Molecular Characterization of High-Risk Human Papillomavirus in Women in Bobo-Dioulasso, Burkina Faso. |
| Q39120200 | Molecular approaches for HPV genotyping and HPV-DNA physical status |
| Q34543310 | Molecular diagnosis of HPV infections |
| Q34196510 | Molecular mapping of high-grade cervical intraepithelial neoplasia shows etiological dominance of HPV16. |
| Q37985256 | Molecular methods for pathogen and microbial community detection and characterization: current and potential application in diagnostic microbiology |
| Q42722235 | Monitoring HPV16/18 immunisation in England and elsewhere. |
| Q50091385 | Monitoring the impact of HPV vaccine in males-Considerations and challenges |
| Q40758755 | Mothers' attitudes in Japan regarding cervical cancer screening correlates with intention to recommend cervical cancer screening for daughters |
| Q34005902 | Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England |
| Q37566009 | Multiple HPV infections in female sex workers in Western Kenya: implications for prophylactic vaccines within this sub population. |
| Q35971959 | Multiple Human Papillomavirus Infections among Chinese Women with and without Cervical Abnormalities: A Population-Based Multi-Center Cross-Sectional Study |
| Q34793429 | Multiplex Identification of Human Papillomavirus 16 DNA Integration Sites in Cervical Carcinomas |
| Q41689179 | Multiplex PCR assay for the rapid identification of human papillomavirus genotypes 16, 18, 45, 35, 66, 33, 51, 58, and 31 in clinical samples. |
| Q35861286 | Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype |
| Q36736614 | Naturally Occurring Major and Minor Capsid Protein Variants of Human Papillomavirus 45 (HPV45): Differential Recognition by Cross-Neutralizing Antibodies Generated by HPV Vaccines. |
| Q41926483 | Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization |
| Q35985515 | Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera |
| Q58085168 | Niche adaptation and viral transmission of human papillomaviruses from archaic hominins to modern humans |
| Q30407482 | No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study |
| Q59353927 | Novel cytomorphologic characteristics suggesting human papillomavirus infection in patients diagnosed as negative for intraepithelial lesion or malignancy and a comparison of diagnostic performance of three human papillomavirus tests |
| Q42281876 | Nucleotide polymorphisms of the human papillomavirus 16 E1 gene |
| Q61815007 | Oncogenic comparison of human papillomavirus type 58 E7 variants |
| Q64080027 | Over Expressed TKTL1, CIP-2A, and B-MYB Proteins in Uterine Cervix Epithelium Scrapings as Potential Risk Predictive Biomarkers in HR-HPV-Infected LSIL/ASCUS Patients |
| Q37203651 | PCR and Genotyping for HPV in Cervical Cancer Patients. |
| Q35244578 | Partition enrichment of nucleotide sequences (PINS)--a generally applicable, sequence based method for enrichment of complex DNA samples |
| Q42204969 | Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer |
| Q34543338 | Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population |
| Q35223393 | Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer |
| Q90740964 | Phylogeny and Classification of Human Papillomavirus (HPV)16 and HPV18 Variants Based on E6 and L1 genes in Tunisian Women with Cervical Lesions |
| Q37288157 | Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes |
| Q57089346 | Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model–Based Analysis |
| Q35021139 | Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex t |
| Q36560944 | Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease |
| Q40180357 | Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in Sicily. |
| Q35610248 | Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France |
| Q37249276 | Potential opportunities to reduce cervical cancer by addressing risk factors other than HPV. |
| Q34492140 | Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins |
| Q36619758 | Predictors of Human Papillomavirus Vaccination in a Large Clinical Population of Males Aged 11 to 26 years in Maryland, 2012-2013 |
| Q37015699 | Prevalence and Genotype Distribution of HPV Infection in China: Analysis of 51,345 HPV Genotyping Results from China's Largest CAP Certified Laboratory |
| Q41162900 | Prevalence and genotype distribution of HPV infection among women in Ningbo, China |
| Q54265480 | Prevalence and type distribution of human papillomavirus (HPV) in Malaysian women with and without cervical cancer: an updated estimate. |
| Q53337708 | Prevalence and type distribution of human papillomavirus in cervical adenocarcinoma in Korean women. |
| Q37269397 | Prevalence characteristics of high-risk human papillomaviruses in women living in Shanghai with cervical precancerous lesions and cancer |
| Q59355661 | Prevalence of "unclassified" HPV genotypes among women with abnormal cytology |
| Q36288661 | Prevalence of HPV 16 and 18 and attitudes toward HPV vaccination trials in patients with cervical cancer in Mali |
| Q33694151 | Prevalence of HPV infection and other risk factors in a Fijian population |
| Q42237614 | Prevalence of HPV16 E1-1374^63nt variants in Greek women |
| Q38971880 | Prevalence of and Risk Factors for Oral Human Papillomavirus Infection With Multiple Genotypes in the United States. |
| Q47547829 | Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions. |
| Q51023169 | Prevalence of human papillomavirus (HPV) types in cervical cancer 2003-2008 in Stockholm, Sweden, before public HPV vaccination. |
| Q41532334 | Prevalence of human papillomavirus and its genotype among 1336 invasive cervical cancer patients in Hunan province, central south China |
| Q35413976 | Prevalence of human papillomavirus genotypes among African women with normal cervical cytology and neoplasia: a systematic review and meta-analysis |
| Q35164233 | Prevalence of human papillomavirus genotypes and associated cervical squamous intraepithelial lesions in HIV-infected women in Botswana |
| Q36650896 | Prevalence of human papillomavirus in the cervical epithelium of Mexican women: meta-analysis. |
| Q58280163 | Prevalence of human papillomavirus in women with invasive cervical carcinoma by HIV status in Kenya and South Africa |
| Q33644013 | Prevalence of human papillomavirus in young Italian women with normal cytology: how should we adapt the national vaccination policy? |
| Q49707769 | Prevalence of human papillomavirus infection among Iranian women using COBAS HPV DNA testing |
| Q37403541 | Prevalence of human papillomavirus type 58 in women with or without cervical lesions in northeast Brazil |
| Q47764270 | Prevalence of human papillomavirus types in cervical lesions from women in rural Western India |
| Q33626255 | Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial |
| Q41502828 | Prognostic significance of TRAIL signalling molecules in cervical squamous cell carcinoma |
| Q37724801 | Prognostic value of human papillomavirus 16/18 genotyping in low-grade cervical lesions preceded by mildly abnormal cytology |
| Q45324634 | Prognostic value of pre-treatment human papilloma virus DNA status in cervical cancer |
| Q33808374 | Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas |
| Q50000948 | Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia. |
| Q38655636 | Projected impact of HPV vaccination and primary HPV screening on cervical adenocarcinoma: Example from Australia. |
| Q45908138 | Promoting cervical screening after introduction of the human papillomavirus vaccine: the effect of repeated mass media campaigns. |
| Q47228634 | Public health approach to prevent cervical cancer in HIV-infected women in Kenya: Issues to consider in the design of prevention programs |
| Q90183581 | RNA-based high-risk HPV genotyping and identification of high-risk HPV transcriptional activity in cervical tissues |
| Q40067782 | Racial/ethnic variation in the prevalence of vaccine-related human papillomavirus genotypes |
| Q35818648 | Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine |
| Q36584268 | Relationship between Metabolic Syndrome and History of Cervical Cancer among a US National Population |
| Q57236189 | Risk Reduction of Cervical Cancer Through HPV Screening and Vaccination—Assumptions and Reality |
| Q36977595 | Risk of cervical HPV infection and prevalence of vaccine-type and other high-risk HPV types among sexually active teens and young women (13-26 years) enrolled in the VALHIDATE study |
| Q60921062 | Role of genomic DNA methylation in detection of cytologic and histologic abnormalities in high risk HPV-infected women |
| Q33770030 | Role of human papillomavirus in oropharyngeal squamous cell carcinoma: A review. |
| Q40134764 | SOX2 as a New Regulator of HPV16 Transcription. |
| Q98289242 | STAT1 expression and HPV16 viral load predict cervical lesion progression |
| Q33952360 | Sequence imputation of HPV16 genomes for genetic association studies |
| Q44582937 | Sequence variation of human papillomavirus type 31 long control region: phylogenetic and functional implications |
| Q34113476 | Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models |
| Q36165724 | Single and multiple high-risk and low-risk Human Papillomavirus association with cervical lesions of 11,224 women in Jakarta |
| Q41749132 | Sites of disruption within E1 and E2 genes of HPV16 and association with cervical dysplasia. |
| Q38925652 | Six-year multi-centre, observational, post-marketing surveillance of the safety of the HPV-16/18 AS04-adjuvanted vaccine in women aged 10-25 years in Korea |
| Q38215895 | Small cell carcinoma of the gynecologic tract: a multifaceted spectrum of lesions |
| Q40096622 | Somatic Host Cell Alterations in HPV Carcinogenesis |
| Q35336871 | Specific genotypes of human papillomavirus in 125 high-grade squamous lesions and invasive cervical cancer cases from Congolese women |
| Q40814748 | Status of Human Papillomavirus Infection in the Ethnic Population in Yunnan Province, China. |
| Q59360544 | Strategies for screening and early detection of anal cancers: A narrative and systematic review and meta-analysis of cytology, HPV testing, and other biomarkers |
| Q100519112 | Structural characterization of a neutralizing mAb H16.001, a potent candidate for a common potency assay for various HPV16 VLPs |
| Q41750462 | Studies on the prevalence of oncogenic HPV types among Lithuanian women with cervical pathology. |
| Q37211860 | Subtype distribution of human papillomavirus in HIV-infected women with cervical intraepithelial neoplasia stages 2 and 3 in Botswana |
| Q38958507 | Survey of Japanese mothers of daughters eligible for human papillomavirus vaccination on attitudes about media reports of adverse events and the suspension of governmental recommendation for vaccination |
| Q38000885 | Susceptibility to cervical cancer: an overview |
| Q34428473 | TNF-alpha rs1800629 polymorphism is not associated with HPV infection or cervical cancer in the Chinese population |
| Q52611125 | Targeted Agents in Cervical Cancer: Beyond Bevacizumab. |
| Q50052586 | Targeted immunotherapy of high-grade cervical intra-epithelial neoplasia: Expectations from clinical trials |
| Q37526148 | The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies. |
| Q35164587 | The DNA load of six high-risk human papillomavirus types and its association with cervical lesions. |
| Q60950662 | The Human Papillomavirus (HPV) E6 Oncoprotein Regulates CD40 Expression via the AT-Hook Transcription Factor AKNA |
| Q34583160 | The association of HPV-16 seropositivity and natural immunity to reinfection: insights from compartmental models |
| Q51208010 | The burden and costs of prevention and management of genital disease caused by HPV in women: a population-based registry study in Finland. |
| Q91841593 | The burden of 14 hr-HPV genotypes in women attending routine cervical cancer screening in 20 states of Mexico: a cross-sectional study |
| Q34089781 | The burden of human papillomavirus infections and related diseases in sub-saharan Africa |
| Q40957119 | The clinical performance of primary HPV screening, primary HPV screening plus cytology cotesting, and cytology alone at a tertiary care hospital |
| Q90611098 | The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia |
| Q90385101 | The current status of immunotherapy for cervical cancer |
| Q90465652 | The development of simultaneous measurement of viral load and physical status for human papillomavirus 16 and 18 co-infection using multiplex quantitative polymerase chain reaction |
| Q34308427 | The distribution of high-risk human papillomaviruses is different in young and old patients with cervical cancer |
| Q38687001 | The health and economic impact of scaling cervical cancer prevention in 50 low- and lower-middle-income countries. |
| Q33585203 | The high prevalence of HPV and HPV16 European variants in cervical and anal samples of HIV-seropositive women with normal Pap test results. |
| Q36541450 | The invisible enemy - how human papillomaviruses avoid recognition and clearance by the host immune system |
| Q50118036 | The landscape of somatic mutations in Indonesian cervical cancer is predominated by the PI3K pathway |
| Q39063760 | The low-risk papillomaviruses |
| Q41602036 | The preliminary study of p53 codon 72 polymorphism and risk of cervical carcinoma in Gabonese women. |
| Q92217999 | The prevalence, trends, and geographical distribution of human papillomavirus infection in China: The pooled analysis of 1.7 million women |
| Q57058899 | The projected timeframe until cervical cancer elimination in Australia: a modelling study |
| Q35038766 | The role of acquired immunity in the spread of human papillomavirus (HPV): explorations with a microsimulation model |
| Q91678136 | Tiempo de Vacunarte (time to get vaccinated): Outcomes of an intervention to improve HPV vaccination rates in a predominantly Hispanic community |
| Q39281387 | Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007. |
| Q93061196 | Transcription factor homeobox D9 is involved in the malignant phenotype of cervical cancer through direct binding to the human papillomavirus oncogene promoter |
| Q100464649 | Transcriptome analysis uncovers the diagnostic value of miR-192-5p/HNF1A-AS1/VIL1 panel in cervical adenocarcinoma |
| Q59114620 | Trends in Biosensors for HPV: Identification and Diagnosis |
| Q47368302 | Trends in incidence, mortality and survival of penile squamous cell carcinoma in Norway 1956-2015. |
| Q38170683 | Trials and projects on cervical cancer and human papillomavirus prevention in sub-Saharan Africa |
| Q34287808 | Tumor-based case-control studies of infection and cancer: muddling the when and where of molecular epidemiology |
| Q37352574 | Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland |
| Q28744257 | Type-specific HPV prevalence in cervical cancer and high-grade lesions in Latin America and the Caribbean: systematic review and meta-analysis |
| Q41655617 | Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation. |
| Q34477097 | Type-specific detection of 30 oncogenic human papillomaviruses by genotyping both E6 and L1 genes |
| Q58694440 | Type-specific high-risk human papillomavirus viral load as a viable triage indicator for high-grade squamous intraepithelial lesion: a nested case–control study |
| Q35530550 | Type-specific human papillomavirus E6/E7 mRNA detection by real-time PCR improves identification of cervical neoplasia |
| Q38635196 | Type-specific human papillomavirus prevalence in cervical intraepithelial neoplasia and cancer in Iran. |
| Q36631402 | Type-specific prevalence of human papillomavirus in women screened for cervical cancer in Labrador, Canada |
| Q36817074 | US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines |
| Q37631033 | Uncommon and rare human papillomavirus genotypes relating to cervical carcinomas |
| Q38133612 | Understanding HPV tests and their appropriate applications |
| Q34141644 | Uneven distribution of human papillomavirus 16 in cervical carcinoma in situ and squamous cell carcinoma in older females: A retrospective database study. |
| Q33592615 | Unique LCR variations among lineages of HPV16, 18 and 45 isolates from women with normal cervical cytology in Ghana |
| Q45008006 | Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance |
| Q34806423 | Vaccinating Girls and Boys with Different Human Papillomavirus Vaccines: Can It Optimise Population-Level Effectiveness? |
| Q47571734 | Viral Oncology: Molecular Biology and Pathogenesis |
| Q42245758 | Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer |
| Q33670688 | Whole-Genome Analysis of Human Papillomavirus Types 16, 18, and 58 Isolated from Cervical Precancer and Cancer Samples in Chinese Women |
| Q40091466 | Whole-genome analysis of human papillomavirus genotypes 52 and 58 isolated from Japanese women with cervical intraepithelial neoplasia and invasive cervical cancer. |
| Q36123728 | Worldwide Prevalence of Human Papillomavirus and Relative Risk of Prostate Cancer: A Meta-analysis |
| Q58378066 | p16/Ki-67 dual staining in cervico-vaginal cytology: Correlation with histology, Human Papillomavirus detection and genotyping in women undergoing colposcopy |
Search more.